CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On May3, 2018, Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), announced its first quarter 2018 financial results. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.
The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing
| Item 2.02 | Financial Statements and Exhibits |
(d) Exhibits
|
Exhibit No. |
Description |
| 99.1 | Press Release dated May3, 2018. |
CATALYST BIOSCIENCES, INC. ExhibitEX-99.1 2 d581037dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Update Announced Korean Ministry of Food and Drug Safety approval to add sixth cohort to the Phase 1/2 trial of CB 2679d/ISU304 in individuals with hemophilia B Raised approximately $106.8 million in an underwritten public offering Received $1.5 million in two milestone payments for neuronal nicotinic receptor (NNR) asset Cash balance of $143.5 million after follow-on financing SOUTH SAN FRANCISCO,…To view the full exhibit click here
About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.